Advertisement

Related Videos

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Advertisement

Advertisement




Apr
21
Today In Oncology
High-Risk Smoldering Multiple Myeloma: BCMA-Directed CAR T-Cell Therapy Shows Activity
‘Prostate Screening Saved My Life’—Is That Really True in Most Cases?
Elisrasib Demonstrates High DCR in KRAS G12C NSCLC
Treatment Modifications and Outcomes for Older Adults With Advanced Cancer Who Prefer Preserving QOL vs Prolonging Survival
Zoldonrasib in Patients With KRAS G12D NSCLC Previously Treated With Chemoimmunotherapy
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo